Skip to content

US · SRRK · BIOTECHNOLOGY

Scholar Rock Holding Corporation (SRRK) intrinsic value and stock valuation

$48.13as of 2026-11-21 · Mkt cap 5.74B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Scholar Rock Holding Corporation DCF and intrinsic value

InvestorsCraft values SRRK with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SRRK’s statements →

Scholar Rock Holding Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 scholarrock.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$0.00
20162025
Net income
-$-377.94M
20162025
Free cash flow
-$-300.64M
20162025
Total equity
$245.5M-1.2% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$33.2M$18.8M
Operating income-$-384.64M-$-252.05M-$-171.29M-$-134.37M-$-129.92M
Net income-$-377.94M-$-246.29M-$-165.79M-$-134.5M-$-131.8M
EPSd-$-3.3M-$-2.47M-$-2.18M-$-2.26M-$-3.59M
Operating cash flow-$-300.04M-$-200.95M-$-145.23M-$-132.69M-$-126.79M
Capital expenditure-$-600K-$-100K-$-70K-$-1.06M-$-5.25M
Free cash flow-$-300.64M-$-201.05M-$-145.3M-$-133.76M-$-132.04M
Total assets$404.3M$474.9M$311M$358.2M$304.4M
Total debt$108.9M$65.1M$61.8M$69.4M$84.5M
Net debt-$-214.61M-$-112.75M-$-40.04M-$-33.88M-$-128.37M
Total equity$245.5M$368.6M$225.2M$260.2M$172.1M
Cash and short-term investments$367.6M$437.3M$279.9M$315.4M$253M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$33.2M$18.8M
Cost of revenue$208.4M$1.94M$2.84M$123M$108.5M
Gross profit-$-208.44M-$-1.94M-$-2.84M-$-89.85M-$-89.65M
Research and development expenses$208.4M$182.6M$119.1M$124.4M$108.5M
Selling, general and administrative expenses$176.2M$67.5M$49.4M$42.6M$40.3M
Other expenses-$-208.44M$0.00$0.00-$-122.54M-$-108.47M
Operating expenses$176.2M$250.1M$168.5M$44.5M$40.3M
Cost and expenses$384.6M$252.1M$171.3M$167.6M$148.7M
Interest income$13.9M$12.7M$0.00$0.00$0.00
Interest expense$6.89M$6.84M$0.00$0.00$0.00
Depreciation and amortization$1.66M$1.94M$2.84M$2.99M$2.63M
Ebitda-$-369.39M-$-237.52M-$-162.94M-$-129.48M-$-129.17M
Operating income-$-384.64M-$-252.05M-$-171.29M-$-134.37M-$-129.92M
Total other income/expenses, net$6.71M$5.76M$5.51M-$-130K-$-1.88M
Income before tax-$-377.94M-$-246.29M-$-165.79M-$-134.5M-$-131.8M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-377.94M-$-246.29M-$-165.79M-$-134.5M-$-131.8M
Weighted average shares outstanding$114.7M$99.8M$76M$59.6M$36.7M
Weighted average diluted shares outstanding$114.7M$99.8M$76M$59.6M$36.7M
Balance sheet
20252024202320222021
Cash and short-term investments$367.6M$437.3M$279.9M$315.4M$253M
Net receivables$0.00$2.15M$1.08M$2.73M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$385.2M$451.2M$288.2M$328M$265.3M
Property, plant and equipment, net$12.1M$18.4M$16M$25.9M$35M
Goodwill and intangible assets$0.00$2.4M$4.07M$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$2.5M
Total non-current assets$19.1M$23.8M$22.8M$30.1M$39.1M
Total assets$404.3M$474.9M$311M$358.2M$304.4M
Accounts payable$10.3M$10.1M$3.46M$3.99M$4.43M
Short-term debt$5.55M$5.77M$8.74M$7.85M$16.4M
Deferred revenue$0.00$0.00$0.00$0.00$33.2M
Total current liabilities$55.4M$46.9M$32.7M$36.4M$64.3M
Long-term debt$103.4M$59.4M$53.1M$61.5M$68.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$103.4M$59.4M$53.1M$61.5M$68.1M
Capital lease obligations$3.66M$15M$11.8M$19.7M$27.1M
Total liabilities$158.8M$106.3M$85.8M$97.9M$132.4M
Common stock$110K$90K$80K$50K$40K
Retained earnings-$-1.3B-$-922.72M-$-676.42M-$-510.63M-$-376.13M
Accumulated other comprehensive income (loss)$90K$160K$90K-$-880K-$-40K
Total equity$245.5M$368.6M$225.2M$260.2M$172.1M
Total investments$44M$259.4M$178.1M$212.1M$42.7M
Total debt$108.9M$65.1M$61.8M$69.4M$84.5M
Net debt-$-214.61M-$-112.75M-$-40.04M-$-33.88M-$-128.37M
Cash flow statement
20252024202320222021
Net income-$-377.94M-$-246.29M-$-165.79M-$-134.5M-$-131.8M
Depreciation and amortization$1.66M$1.94M$2.84M$2.99M$2.63M
Stock-based compensation$75.6M$36.6M$27.1M$27.7M$23.2M
Change in working capital-$-1.05M$6.59M-$-10.61M-$-34.39M-$-28.44M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$210K$6.63M-$-530K-$-250K$1.02M
Net cash provided by operating activities-$-300.04M-$-200.95M-$-145.23M-$-132.69M-$-126.79M
Investments in property, plant and equipment-$-600K-$-100K-$-70K-$-1.06M-$-5.25M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$218.7M-$-76.06M$41.1M-$-171.7M$134.3M
Common stock issued$179.3M$324.4M$97.7M$195.3M$13.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$228.4M$353M$102.6M$194.8M$45M
Net change in cash$147.1M$76M-$-1.51M-$-109.56M$52.5M
Cash at end of period$327.3M$180.3M$104.3M$105.8M$215.3M
Operating cash flow-$-300.04M-$-200.95M-$-145.23M-$-132.69M-$-126.79M
Capital expenditure-$-600K-$-100K-$-70K-$-1.06M-$-5.25M
Free cash flow-$-300.64M-$-201.05M-$-145.3M-$-133.76M-$-132.04M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Scholar Rock Holding Corporation

        Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

        CEO
        David L. Hallal
        Employees
        289
        Beta
        0.68

        Explore

        Frequently asked questions

        What is the intrinsic value of Scholar Rock Holding Corporation (SRRK)?

        InvestorsCraft does not currently publish an intrinsic value for SRRK. How the IC value is calculated.

        Is SRRK undervalued?

        InvestorsCraft does not publish an undervaluation signal for SRRK at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.